



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	December 15, 2015 October 3, 2019, March 18, 2025

Daptomycin

LENGTH OF AUTHORIZATION:

Complicated skin and skin structure infections: Maximum length of therapy - 14 days

Staphylococcus aureus bacteremia: Maximum length of therapy - 6 weeks

REVIEW CRITERIA:

Complicated skin and skin structure infections:

- Patient has been diagnosed with complicated skin and skin structure infection (cSSSI) caused by susceptible isolates of the following gram-positive bacteria: *Staphylococcus aureus* (including methicillin-resistant isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae* subsp. *equisimilis*, and *Enterococcus faecalis* (vancomycin-susceptible isolates only) **AND**
- Patient must have medical documentation of trial and failure of vancomycin for the current active infection or a culture and sensitivity report indicating the organism is resistant to vancomycin or the patient has a documented intolerance to vancomycin.

Staphylococcus aureus bacteremia

- Patient has been diagnosed with *Staphylococcus aureus* bloodstream infection (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates **AND**
- Patient must have medical documentation of trial and failure of vancomycin for the current active infection or a culture and sensitivity report indicating the organism is resistant to vancomycin or the patient has a documented intolerance to vancomycin.

DOSING & ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as: 350 mg and 500 mg lyophilized powder for reconstitution in a single-dose vial and 350 mg/50 mL, 500 mg/50mL, 700 mg/100mL, and 1,000 mg/100mL solution for injection.